Fate Therapeutics Announces CMO Departure and Interim Appointment
Ticker: FATE · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1434316
| Field | Detail |
|---|---|
| Company | Fate Therapeutics Inc (FATE) |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $495,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel, cmo
TL;DR
Fate Therapeutics' CMO is out, interim CMO in. Keep an eye on strategy shifts.
AI Summary
On October 10, 2025, Fate Therapeutics, Inc. filed an 8-K report detailing the departure of Dr. Wayne Johnson as Chief Medical Officer. The company also announced the appointment of Dr. Nicole A. Shinton as interim Chief Medical Officer. Additionally, the filing includes information regarding compensatory arrangements for certain officers.
Why It Matters
This filing signals a leadership change in a key medical role, which could impact the company's strategic direction and drug development pipeline.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can indicate internal challenges or strategic shifts that may affect future performance.
Key Players & Entities
- Fate Therapeutics, Inc. (company) — Registrant
- Dr. Wayne Johnson (person) — Departing Chief Medical Officer
- Dr. Nicole A. Shinton (person) — Appointed Interim Chief Medical Officer
- October 10, 2025 (date) — Date of earliest event reported
- 12278 Scripps Summit Drive, San Diego, California 92131 (location) — Principal Executive Offices
FAQ
Who has been appointed as the interim Chief Medical Officer for Fate Therapeutics?
Dr. Nicole A. Shinton has been appointed as the interim Chief Medical Officer.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 10, 2025.
What was Dr. Wayne Johnson's role at Fate Therapeutics before his departure?
Dr. Wayne Johnson was the Chief Medical Officer.
What is the principal executive office address for Fate Therapeutics?
The principal executive office is located at 12278 Scripps Summit Drive, San Diego, California 92131.
What other items are mentioned in the 8-K filing besides officer changes?
The filing also includes information on Regulation FD Disclosure and Financial Statements and Exhibits.
Filing Stats: 1,244 words · 5 min read · ~4 pages · Grade level 9.9 · Accepted 2025-10-14 16:02:55
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value FATE Nasdaq Global Market
- $495,000 — to receive: An annual base salary of $495,000, and is eligible to receive an annual p
Filing Documents
- fate-20251010.htm (8-K) — 63KB
- fate-ex10_1.htm (EX-10.1) — 43KB
- fate-ex99_1.htm (EX-99.1) — 20KB
- img158830969_0.jpg (GRAPHIC) — 20KB
- 0001193125-25-238989.txt ( ) — 273KB
- fate-20251010.xsd (EX-101.SCH) — 24KB
- fate-20251010_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 14, 2025, the Company issued a press release announcing Mr. Adawi's appointment as Chief Financial Officer of the Company. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Offer Letter between the Company and Kamal Adawi, dated as of October 13, 2025 99.1 Press Release issued by Fate Therapeutics, Inc. on October 14, 2025, furnished herewith 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FATE THERAPEUTICS, INC. Date: October 14, 2025 By: /s/ Bahram Valamehr Bahram Valamehr, Ph.D., M.B.A. President and Chief Executive Officer